BELL Therapeutics Inc.

Seoul

OncologyvaccinePhase II

What changed

Phase II trial registered: Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer

1w agoTrial registeredJul 7, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,843 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
NA registered
Jun 1, 2026
Insomnia, Sleep Initiation and Maintenance Disorders · NOT_YET_RECRUITING · sponsor: BELL Therapeutics Inc. · Clinical Investigation to Observe the Long-term Safety and Efficacy of the Digital Medical Device 'BELL-001' in Patients Diagnosed With Insomnia
ClinicalTrials.gov · NCT07582809 (opens the source filing in a new tab)
Trial
NA registered
Jan 15, 2026
Insomnia, Sleep Initiation and Maintenance Disorders · NOT_YET_RECRUITING · sponsor: BELL Therapeutics Inc. · Sleep Efficacy Randomized Evaluation of a Novel Digital Therapeutic for Insomnia
ClinicalTrials.gov · NCT07295431 (opens the source filing in a new tab)
Patent
Patent granted
Jan 21, 2025
assignee: DANA-FARBER CANCER INSTITUTE, INC. · IL-23R ANTAGONISTS TO REPROGRAM INTRATUMORAL T REGULATORY CELLS INTO EFFECTOR CELLS
USPTO · US 12202904 (opens the source filing in a new tab)
Patent
Patent assigned
Oct 18, 2024
assignee: DANA-FARBER CANCER INSTITUTE, INC. · IL-23R ANTAGONISTS TO REPROGRAM INTRATUMORAL T REGULATORY CELLS INTO EFFECTOR CELLS
USPTO · US 12202904 (opens the source filing in a new tab)
Trial
PHASE2 registered
May 26, 2023
Head and Neck Squamous Cell Carcinoma · COMPLETED · sponsor: Yonsei University · Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients
ClinicalTrials.gov · NCT05294900 (opens the source filing in a new tab)
Trial
PHASE2 registered
Apr 7, 2023
Non-small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Yonsei University · Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib
ClinicalTrials.gov · NCT05786430 (opens the source filing in a new tab)
Trial
PHASE2 registered
Sep 1, 2022
Non Small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Yonsei University · Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)
ClinicalTrials.gov · NCT05206812 (opens the source filing in a new tab)
Trial
PHASE2 registered
Apr 15, 2022
Head and Neck Squamous Cell Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Yonsei University · HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy
ClinicalTrials.gov · NCT05280457 (opens the source filing in a new tab)
Trial
PHASE2 registered
Mar 1, 2022
Head and Neck Squamous Cell Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Yonsei University · Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer
ClinicalTrials.gov · NCT05286060 (opens the source filing in a new tab)
Trial
PHASE2 registered
Feb 7, 2022
Non-small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Yonsei University · Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
ClinicalTrials.gov · NCT06268210 (opens the source filing in a new tab)
Trial
PHASE2 registered
Feb 7, 2022
Locally Advanced Nasopharyngeal Carcinoma · RECRUITING · sponsor: Yonsei University · Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
ClinicalTrials.gov · NCT04910347 (opens the source filing in a new tab)
Trial
NA registered
Dec 3, 2020
Head and Neck Squamous Cell Carcinoma (HNSCC) · COMPLETED · sponsor: Yonsei University · A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
ClinicalTrials.gov · NCT04603248 (opens the source filing in a new tab)
Trial
Study registered
Apr 8, 2020
Non Small Cell Lung Cancer · COMPLETED · sponsor: Yonsei University · A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients
ClinicalTrials.gov · NCT04312308 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.97name similarity 100% · semantic similarity 89% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the patent record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the patent record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the trial record at 0.32no candidate cleared the review threshold

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
1w agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy
5w agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
5w agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
5w agoTrial completedSource (opens the source filing in a new tab)
Phase II trial registered: Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients
7w agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients
7w agoTrial completedSource (opens the source filing in a new tab)
Study registered, no phase assigned: Clinical Investigation to Observe the Long-term Safety and Efficacy of the Digital Medical Device 'BELL-001' in Patients Diagnosed With Insomnia
2mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer
5mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients
5mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients
5mo agoTrial completedSource (opens the source filing in a new tab)
Phase II trial registered: Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib
5mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)
5mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Sleep Efficacy Randomized Evaluation of a Novel Digital Therapeutic for Insomnia
7mo agoTrial registeredSource (opens the source filing in a new tab)
Patent granted · IL-23R ANTAGONISTS TO REPROGRAM INTRATUMORAL T REGULATORY CELLS INTO EFFECTOR CELLS
Jan 2025Patent grantedSource (opens the source filing in a new tab)
Patent assigned · IL-23R ANTAGONISTS TO REPROGRAM INTRATUMORAL T REGULATORY CELLS INTO EFFECTOR CELLS
Oct 2024Patent assignedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

NA registered

NA registered

Patent granted

Patent assigned

PHASE2 registered

PHASE2 registered

PHASE2 registered

PHASE2 registered

PHASE2 registered

PHASE2 registered

PHASE2 registered

NA registered

Study registered